AR085572A1 - Metodos de tratamiento dirigidos de la degeneracion lobular frontotemporal - Google Patents
Metodos de tratamiento dirigidos de la degeneracion lobular frontotemporalInfo
- Publication number
- AR085572A1 AR085572A1 ARP120101007A ARP120101007A AR085572A1 AR 085572 A1 AR085572 A1 AR 085572A1 AR P120101007 A ARP120101007 A AR P120101007A AR P120101007 A ARP120101007 A AR P120101007A AR 085572 A1 AR085572 A1 AR 085572A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- independently selected
- nr50r51
- halo
- Prior art date
Links
- 230000007850 degeneration Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 22
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- -1 -OH Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467989P | 2011-03-26 | 2011-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085572A1 true AR085572A1 (es) | 2013-10-09 |
Family
ID=45931040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101007A AR085572A1 (es) | 2011-03-26 | 2012-03-26 | Metodos de tratamiento dirigidos de la degeneracion lobular frontotemporal |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140179678A1 (https=) |
| EP (1) | EP2691099A1 (https=) |
| JP (2) | JP5995956B2 (https=) |
| CN (2) | CN103561747B (https=) |
| AR (1) | AR085572A1 (https=) |
| AU (1) | AU2012236852A1 (https=) |
| CA (1) | CA2831291A1 (https=) |
| IL (1) | IL228405A0 (https=) |
| MX (1) | MX2013011096A (https=) |
| RU (1) | RU2013147810A (https=) |
| TW (1) | TW201247205A (https=) |
| UY (1) | UY33973A (https=) |
| WO (1) | WO2012135097A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149836B2 (en) | 2014-03-21 | 2018-12-11 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
| US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| AR119149A1 (es) * | 2019-06-12 | 2021-11-24 | Arkuda Therapeutics | Derivados de isoquinolina como moduladores de la progranulina |
| US20230201269A1 (en) * | 2020-04-24 | 2023-06-29 | Spinalcyte, Llc | Treatment of frontotemporal dementia using fibroblasts and products thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| CN101573333B (zh) * | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US20090291444A1 (en) * | 2008-03-31 | 2009-11-26 | Jason Eriksen | Methods and materials for detecting and treating dementia |
| US20110288070A1 (en) * | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137499A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
-
2012
- 2012-03-26 AR ARP120101007A patent/AR085572A1/es unknown
- 2012-03-26 JP JP2014502654A patent/JP5995956B2/ja not_active Expired - Fee Related
- 2012-03-26 MX MX2013011096A patent/MX2013011096A/es not_active Application Discontinuation
- 2012-03-26 CN CN201280025073.5A patent/CN103561747B/zh not_active Expired - Fee Related
- 2012-03-26 CN CN201610143729.3A patent/CN105748484A/zh active Pending
- 2012-03-26 TW TW101110441A patent/TW201247205A/zh unknown
- 2012-03-26 EP EP12712497.2A patent/EP2691099A1/en not_active Withdrawn
- 2012-03-26 US US14/007,572 patent/US20140179678A1/en not_active Abandoned
- 2012-03-26 CA CA2831291A patent/CA2831291A1/en not_active Abandoned
- 2012-03-26 WO PCT/US2012/030527 patent/WO2012135097A1/en not_active Ceased
- 2012-03-26 RU RU2013147810/15A patent/RU2013147810A/ru not_active Application Discontinuation
- 2012-03-26 UY UY0001033973A patent/UY33973A/es not_active Application Discontinuation
- 2012-03-26 AU AU2012236852A patent/AU2012236852A1/en not_active Abandoned
-
2013
- 2013-09-12 IL IL228405A patent/IL228405A0/en unknown
-
2016
- 2016-08-23 JP JP2016162758A patent/JP2017019826A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201247205A (en) | 2012-12-01 |
| JP2014511848A (ja) | 2014-05-19 |
| CN103561747A (zh) | 2014-02-05 |
| IL228405A0 (en) | 2013-12-31 |
| JP5995956B2 (ja) | 2016-09-21 |
| EP2691099A1 (en) | 2014-02-05 |
| CN105748484A (zh) | 2016-07-13 |
| CA2831291A1 (en) | 2012-10-04 |
| RU2013147810A (ru) | 2015-05-10 |
| US20140179678A1 (en) | 2014-06-26 |
| AU2012236852A1 (en) | 2013-09-26 |
| CN103561747B (zh) | 2016-04-06 |
| MX2013011096A (es) | 2014-06-06 |
| WO2012135097A1 (en) | 2012-10-04 |
| JP2017019826A (ja) | 2017-01-26 |
| UY33973A (es) | 2012-10-31 |
| NZ615177A (en) | 2016-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
| CR20140091A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| UY35395A (es) | Inhibidores de bromodominios tetracíclicos | |
| UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
| ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
| MX381849B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| CO7240410A2 (es) | Inhibidores macrocíclicos de virus flaviviridae | |
| CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| CR20140089A (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
| AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| CO6630162A2 (es) | Derivados del ácido 1-amino -2-ciclopropiletilboronico | |
| UY34264A (es) | Compuestos de fórmula genérica 4-(8-metoxi-1-(1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H- imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y sus sales. | |
| CR20120418A (es) | Inhibidores de virus flaviviridae | |
| AR101175A1 (es) | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| ECSP15000435A (es) | Inhibidores macrocíclicos de virus flaviviridae | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| AR087913A1 (es) | Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| EA201390766A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |